spacer
spacer

PDBsum entry 2ahx

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Cell cycle,signaling protein PDB id
2ahx

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
611 a.a. *
Ligands
NAG ×16
SO4 ×3
Metals
YT3
Waters ×138
* Residue conservation analysis
PDB id:
2ahx
Name: Cell cycle,signaling protein
Title: Crystal structure of erbb4/her4 extracellular domain
Structure: Receptor tyrosine-protein kinase erbb-4. Chain: a, b. Fragment: extracellular domain. Synonym: p180erbb4. Tyrosine kinase-type cell surface receptor her4. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: erbb4, her4. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Expression_system_cell: hampster ovary cells.
Resolution:
2.40Å     R-factor:   0.237     R-free:   0.265
Authors: S.Bouyain,P.A.Longo,S.Li,K.M.Ferguson,D.J.Leahy
Key ref:
S.Bouyain et al. (2005). The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A, 102, 15024-15029. PubMed id: 16203964 DOI: 10.1073/pnas.0507591102
Date:
28-Jul-05     Release date:   27-Sep-05    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
Q15303  (ERBB4_HUMAN) -  Receptor tyrosine-protein kinase erbB-4 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1308 a.a.
611 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: E.C.2.7.10.1  - receptor protein-tyrosine kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
L-tyrosyl-[protein]
+
ATP
Bound ligand (Het Group name = NAG)
matches with 47.62% similarity
= O-phospho-L-tyrosyl-[protein]
+ ADP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
DOI no: 10.1073/pnas.0507591102 Proc Natl Acad Sci U S A 102:15024-15029 (2005)
PubMed id: 16203964  
 
 
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
S.Bouyain, P.A.Longo, S.Li, K.M.Ferguson, D.J.Leahy.
 
  ABSTRACT  
 
The human ErbB family of receptor tyrosine kinases comprises the epidermal growth factor receptor (EGFR/ErbB1/HER1), ErbB2 (HER2/Neu), ErbB3 (HER3), and ErbB4 (HER4). ErbBs play fundamental roles in cell growth and differentiation events in embryonic and adult tissues, and inappropriate ErbB activity has been implicated in several human cancers. We report here the 2.4 A crystal structure of the extracellular region of human ErbB4 in the absence of ligand and show that it adopts a tethered conformation similar to inactive forms of ErbB1 and ErbB3. This structure completes the gallery of unliganded ErbB receptors and demonstrates that all human ligand-binding ErbBs adopt the autoinhibited conformation. We also show that the binding of neuregulin-1beta to ErbB4 and ErbB3 and the binding of betacellulin to both ErbB4 and ErbB1 does not decrease at low pH, unlike the binding of epidermal growth factor and transforming growth factor-alpha to ErbB1. These results indicate an important role for ligand in determining pH-dependent binding and may explain different responses observed when the same ErbB receptor is stimulated by different ligands.
 
  Selected figure(s)  
 
Figure 2.
Fig. 2. Structure of sErbB4. (A) Ribbon diagram of sErbB4. Domains I, II, III, and IV are colored blue, green, yellow, and red, respectively. The N and C termini are indicated by the letters N and C. (B) Surface representation of sErbB4. The intramolecular contact between domains II and IV is boxed. (C) Domain II/IV contact in ligand-binding sErbBs. Residues at the tether between domains II and IV of sErbB4 are shown in green (domain II) and red (domain IV). The equivalent residues from tethered sErbB1 and sErbB3 are shown in gray and white, respectively (3, 6). The buried surface areas and the surface complementarity coefficients for each tether are indicated in the legend.
Figure 3.
Fig. 3. Comparison of ligand-binding surfaces in sErbB1 and sErbB4. (A) Conservation of sErbB1 TGF- -binding residues in sErbB4. Residues with atoms within4Åofa TGF- residue are shown in red on surface representations of sErbB1 domains I and III (4). Residues that are strictly conserved between the ErbB1 ligand-binding site and ErbB4 are colored blue on surface representations of sErbB4. (B) Electrostatic potential on the ligand-binding surfaces of ErbB1 and ErbB4. Regions with negative electrostatic potential are colored red and regions with positive electrostatic potential are colored blue (scale ± 10 e/kT).
 
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
22785351 Y.Yarden, and G.Pines (2012).
The ERBB network: at last, cancer therapy meets systems biology.
  Nat Rev Cancer, 12, 553-563.  
20723758 D.Alvarado, D.E.Klein, and M.A.Lemmon (2010).
Structural basis for negative cooperativity in growth factor binding to an EGF receptor.
  Cell, 142, 568-579.
PDB codes: 3ltf 3ltg
  20212358 F.Cymer, and D.Schneider (2010).
Transmembrane helix-helix interactions involved in ErbB receptor signaling.
  Cell Adh Migr, 4, 299-312.  
20872851 F.Zhang, S.Weggler, M.J.Ziller, L.Ianeselli, B.S.Heck, A.Hildebrandt, O.Kohlbacher, M.W.Skoda, R.M.Jacobs, and F.Schreiber (2010).
Universality of protein reentrant condensation in solution induced by multivalent metal ions.
  Proteins, 78, 3450-3457.  
21119106 L.Chen, J.Placone, L.Novicky, and K.Hristova (2010).
The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
  Sci Signal, 3, ra86.  
19898750 T.Otani, T.Hashizume, T.Nagaoka, T.Fukuda, C.K.Tang, D.S.Salomon, and M.Seno (2010).
Production of biologically active IgG hinge-tag soluble epidermal growth factor receptors (ErbB).
  Biotechnol Lett, 32, 361-366.  
19518076 C.Qiu, M.K.Tarrant, T.Boronina, P.A.Longo, J.M.Kavran, R.N.Cole, P.A.Cole, and D.J.Leahy (2009).
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
  Biochemistry, 48, 6624-6632.  
19718021 D.Alvarado, D.E.Klein, and M.A.Lemmon (2009).
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
  Nature, 461, 287-291.
PDB code: 3i2t
  20357902 K.L.Carraway, and G.A.Kozloski (2009).
Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights.
  F1000 Biol Rep, 1, 1-4.  
18992239 K.R.Schmitz, and K.M.Ferguson (2009).
Interaction of antibodies with ErbB receptor extracellular regions.
  Exp Cell Res, 315, 659-670.  
19486684 L.Chen, M.Merzlyakov, T.Cohen, Y.Shai, and K.Hristova (2009).
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers.
  Biophys J, 96, 4622-4630.  
  19048033 P.Jin, J.Zhang, M.Beryt, L.Turin, C.Brdlik, Y.Feng, X.Bai, J.Liu, B.Jorgensen, and H.M.Shepard (2009).
Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
  Mol Med, 15, 11-20.  
19289058 S.E.Telesco, and R.Radhakrishnan (2009).
Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.
  Biophys J, 96, 2321-2334.  
19376231 S.O'Connor, E.Li, B.S.Majors, L.He, J.Placone, D.Baycin, M.J.Betenbaugh, and K.Hristova (2009).
Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xL.
  Protein Expr Purif, 67, 41-47.  
19718025 T.D.Prickett, N.S.Agrawal, X.Wei, K.E.Yates, J.C.Lin, J.R.Wunderlich, J.C.Cronin, P.Cruz, S.A.Rosenberg, and Y.Samuels (2009).
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
  Nat Genet, 41, 1127-1132.  
18334220 C.Qiu, M.K.Tarrant, S.H.Choi, A.Sathyamurthy, R.Bose, S.Banjade, A.Pal, W.G.Bornmann, M.A.Lemmon, P.A.Cole, and D.J.Leahy (2008).
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
  Structure, 16, 460-467.
PDB codes: 3bbt 3bbw 3bce
18404164 G.Sithanandam, and L.M.Anderson (2008).
The ERBB3 receptor in cancer and cancer gene therapy.
  Cancer Gene Ther, 15, 413-448.  
18394559 J.Schmiedel, A.Blaukat, S.Li, T.Knöchel, and K.M.Ferguson (2008).
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
  Cancer Cell, 13, 365-373.
PDB codes: 3c08 3c09
18573086 K.M.Ferguson (2008).
Structure-based view of epidermal growth factor receptor regulation.
  Annu Rev Biophys, 37, 353-373.  
18288481 K.Roepstorff, L.Grøvdal, M.Grandal, M.Lerdrup, and B.van Deurs (2008).
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.
  Histochem Cell Biol, 129, 563-578.  
18259690 M.J.Wieduwilt, and M.M.Moasser (2008).
The epidermal growth factor receptor family: biology driving targeted therapeutics.
  Cell Mol Life Sci, 65, 1566-1584.  
18031935 M.Landau, and N.Ben-Tal (2008).
Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors.
  Biochim Biophys Acta, 1785, 12-31.  
18365190 O.Samna Soumana, N.Garnier, and M.Genest (2008).
Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search.
  Eur Biophys J, 37, 851-864.  
18275813 S.Li, P.Kussie, and K.M.Ferguson (2008).
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
  Structure, 16, 216-227.
PDB codes: 3b2u 3b2v
17280834 C.W.Ward, M.C.Lawrence, V.A.Streltsov, T.E.Adams, and N.M.McKern (2007).
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.
  Trends Biochem Sci, 32, 129-137.  
17508401 D.J.Riese, R.M.Gallo, and J.Settleman (2007).
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
  Bioessays, 29, 558-565.  
17314037 E.M.Bublil, and Y.Yarden (2007).
The EGF receptor family: spearheading a merger of signaling and therapeutics.
  Curr Opin Cell Biol, 19, 124-134.  
17671639 H.Zhang, A.Berezov, Q.Wang, G.Zhang, J.Drebin, R.Murali, and M.I.Greene (2007).
ErbB receptors: from oncogenes to targeted cancer therapies.
  J Clin Invest, 117, 2051-2058.  
17697999 J.P.Dawson, Z.Bu, and M.A.Lemmon (2007).
Ligand-induced structural transitions in ErbB receptor extracellular domains.
  Structure, 15, 942-954.  
17274834 R.Landgraf (2007).
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
  Breast Cancer Res, 9, 202.  
16819515 S.L.Chen, S.T.Lin, T.C.Tsai, W.C.Hsiao, and Y.P.Tsao (2007).
ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein.
  Oncogene, 26, 42-53.  
17030621 W.Xu, X.Yuan, K.Beebe, Z.Xiang, and L.Neckers (2007).
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
  Mol Cell Biol, 27, 220-228.  
17155902 A.Yasmeen, T.A.Bismar, and A.E.Al Moustafa (2006).
ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.
  Future Oncol, 2, 765-781.  
16865534 C.Sweeney, J.K.Miller, D.L.Shattuck, and K.L.Carraway (2006).
ErbB receptor negative regulatory mechanisms: implications in cancer.
  J Mammary Gland Biol Neoplasia, 11, 89-99.  
17026767 R.A.Stein, and J.V.Staros (2006).
Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
  BMC Evol Biol, 6, 79.  
17125150 R.L.Rich, and D.G.Myszka (2006).
Survey of the year 2005 commercial optical biosensor literature.
  J Mol Recognit, 19, 478-534.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer